LongIBRXJul 2026
ImmunityBio, Inc.
ImmunityBio's valuation is being assessed against the commercial capacity of its Anktiva franchise. The manager highlights manufacturing facilities capable of producing one…
IBRX
Which hedge funds are long IBRX?
1 published idea on ImmunityBio, Inc. across 1 fund — 1 long and 0 short.
ImmunityBio hedge fund investment theses
Each stock pitch below comes from a fund manager's own investor letter, not a 13F filing, so it carries the reasoning behind the portfolio position on ImmunityBio: the full investment thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.